Patients treated for constipation report more BM satisfaction with linaclotide

  • Taylor DCA & al.
  • J Clin Gastroenterol
  • 29 jul. 2019

  • de Craig Hicks
  • Clinical Essentials
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

Takeaway

  • Patients with constipation treated with linaclotide (Linzess) are more likely to report bowel movement (BM) satisfaction than those undergoing other treatments.

Why this matters

  • Understanding patient perceptions of treatment effects may help clinicians manage expectations and inform clinical decision making.

Study design

  • Researchers studied BM diaries completed by patients with either irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (N=1786; mean age, 46.8 years; 94.2% women; 83.3% white; BMs reported, 26,524), using logistic regression to analyze relationships among stool consistency, medication use, and BM satisfaction.
  • They classified BMs as loose or watery stools (LoWS), hard or lumpy stools (HoLS), or intermediate (neither LoWS nor HoLS).
  • Funding: Allergan; Ironwood Pharmaceuticals.

Key results

  • Overall BM satisfaction was highest for intermediate stools (61.2%), followed by LoWS (51.2%) and HoLS (19.4%).
  • Treatment with linaclotide was associated with higher odds of patient-reported BM satisfaction than treatment with other medications (OR, 1.23; P=.027).

Limitations

  • Results may not apply to uninsured and older populations.
  • The study did not assess other factors affecting BM satisfaction, such as straining, urgency, or sense of complete evacuation.